

## Contacts



### Isabelle Dupin-Roger

Director of External Innovation

Neurology & Immuno-Inflammation Therapeutic Areas

Mobile: +33 6 87 25 03 73

[isabelle.dupin-roger@servier.com](mailto:isabelle.dupin-roger@servier.com)

## Active Neurology Partnerships



## Areas of interest

# Neuroscience



- Partners looking for accelerative collaboration and clinical enablement
- Targeting sub-populations and rare forms of neurodegenerative disease

### Target-to-hit up to lead optimisation stage

#### Biological mechanisms

Normalising disease-disrupted protein homeostasis

- Clearance of toxic proteins (Autophagic-Lysosomal Network ); Targeted degradation (AUTAC, PROTAC, LYTAC)
- Regulation of transcription and translation of targets

#### Target class

Targeting RNA/ proteins genetically and causally linked to disease

#### Indications

- Multiple System Atrophy
- Familial Amyotrophic Lateral Sclerosis
- Hereditary forms of Parkinson Disease
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy

#### Modality

- Small molecules
- PROTAC
- Oligonucleotides

#### Drug delivery

- Central administration with a medical devices
- Systemic administration for CNS RNA technologies
- Brain distribution and targeted
- Brain distribution and targeted delivery (formulation)
- Technologies to improve the efficacy/specificity of cellular delivery (ASO)

#### Exclusions

- Epilepsy, multiple sclerosis, pain, psychiatry, infectious diseases
- Antibodies, cell therapy, vaccination

## Partnering with Servier

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.

## A partner of choice

### A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

### A partner with a global presence

With €4.7Bn of revenue in 2020 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

### A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners

### A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets

## Our areas of interest



### Oncology

#### Discovery & Early Clinical Focus

##### Cancer cell Targeting

- Apoptosis (BCL2 family; extrinsic cell death)
- Novel oncogenes, oncogene stability regulators
- Epigenetic regulators (with biomarker validation)
- Synthetic lethality associated with genetic defect

##### Immuno-oncology

- Stroma/ Tumor micro-environment (e.g., genetically-driven immune contexture)
- T cell activation (e.g. intracellular immune checkpoints)
- Immunosuppression (e.g. Treg targeting)
- Innate immunity (e.g. Type I interferon pathway)

##### Modalities

- Small molecules (Discovery to Early Clinical stage)
- mAb/bispecifics (Early Clinical stage)

##### Late stage and commercial opportunities

- We are actively looking at strengthening our portfolio and licensing-in/acquiring commercial and late-stage products (on market ~2023/4)



### Immuno-inflammation

#### Inflammatory & autoimmune disease

- Lupus
- Primary Sjögren syndrome
- Systemic sclerosis
- And other diseases sharing similar pathophysiological mechanisms

##### Modalities

- small molecules
- mAb/bispecifics



### Neuroscience

- Multiple System Atrophy
- Familial Amyotrophic lateral sclerosis
- Hereditary forms of Parkinson's Disease
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy

##### Modalities

- Small molecules
- ASO
- PROTAC



### Cardiovascular & Metabolism diseases

Acquire or license market-ready or mature assets for some geographies